Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity

The design of kinase inhibitors targeting the oncogenic kinase BCR-ABL constitutes a promising paradigm for treating chronic myeloid leukaemia (CML). Nevertheless, the efficacy of imatinib, the first FDA-approved targeted therapy for CML, is curbed by the emergence of resistance. Herein, we report t...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Damasy, Ashraf K., Jin, Heewon, Park, Jung Woo, Kim, Hyun Ji, Khojah, Hanan, Seo, Seon Hee, Lee, Ju-Hyeon, Bang, Eun-Kyoung, Keum, Gyochang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026764/
https://www.ncbi.nlm.nih.gov/pubmed/36927348
http://dx.doi.org/10.1080/14756366.2023.2189097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026764/
https://www.ncbi.nlm.nih.gov/pubmed/36927348
http://dx.doi.org/10.1080/14756366.2023.2189097

Ejemplares similares